SN-38 (Synonyms: 7-Ethyl-10-hydroxycamptothecin)

目录号: HY-13704 纯度: 99.94%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

SN-38 是拓扑异构酶 I (Topoisomerase I) 抑制剂伊立替康的活性代谢产物。SN-38 抑制 DNA 合成和 RNA 合成的 IC₅₀ 分别为 0.077 和 1.3 μM。SN-38 是 sacituzumab govitecan (HY -132254) 的有效载荷。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SN-38 Chemical Structure

CAS No. : 86639-52-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥470	In-stock
50 mg	￥420	In-stock
100 mg	￥580	In-stock
500 mg	￥1450	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of SN-38:

SN-38-d₃ In-stock
SN-38 (Standard) In-stock

MCE 顾客使用本产品发表的 69 篇科研文献

SN-38 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看所有亚型

Topoisomerase Topo I Topo II

查看 ADC Payload 亚型特异性产品:

查看所有亚型

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC₅₀s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254)^[1]^[2]^[3]^[4]^[5].

IC₅₀ & Target^[1]

Topoisomerase I

Camptothecins

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
16HBE14o-	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against human 16HBE cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human 16HBE cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
A2780	IC₅₀	0.009 μM Compound: 3, SN38	Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
A498	GI₅₀	0.22 μM Compound: SN-38	Growth inhibition of human A498 cells by Cell-titer96 assay Growth inhibition of human A498 cells by Cell-titer96 assay	[PMID: 33492141]
A549	IC₅₀	0.018 μM Compound: SN-38	Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
A549	IC₅₀	0.028 μM Compound: 1d; SN38	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
A549	IC₅₀	0.047 μM Compound: SN-38	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21470864]
A549	IC₅₀	0.08 μM Compound: SN-38	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 18986807]
A549	IC₅₀	0.088 μM Compound: 5, SN-38	Antitumor activity against human A549/ATCC cells by SRB method Antitumor activity against human A549/ATCC cells by SRB method	[PMID: 19541483]
A549	IC₅₀	0.2 μM Compound: SN38	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30169038]
A549	IC₅₀	0.259 μM Compound: 5, SN-38	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 24529870]
A549	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-negative human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-negative human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
A549	IC₅₀	1.62 nM Compound: 14; SN-38	Cytotoxicity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
A549	IC₅₀	1.62 nM Compound: SN-38	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30115492]
A549	IC₅₀	11 nM Compound: SN38	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
A549	IC₅₀	11.9 nM Compound: SN-38	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay	[PMID: 34963283]
A549	IC₅₀	16 nM Compound: SN-38	In Vitro cytotoxicity against human lung cancer cell line (A549) In Vitro cytotoxicity against human lung cancer cell line (A549)	[PMID: 11334569]
A549	IC₅₀	2.72 nM Compound: 5, SN-38	Cytotoxicity against human A549 cells assessed as growth inhibition after 3 days by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 24529870]
A549	IC₅₀	3.8 nM Compound: SN-38	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 120 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 120 hrs by CCK-8 assay	[PMID: 34963283]
A549	IC₅₀	45.4 nM Compound: SN-38	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
A549	IC₅₀	6.6 μM Compound: SN-38	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
ACHN	GI₅₀	5.9 nM Compound: 4; SN-38	Antiproliferative activity against human ACHN cells after 48 hrs by SRB assay Antiproliferative activity against human ACHN cells after 48 hrs by SRB assay	[PMID: 30553626]
Bel-7402	IC₅₀	13 nM Compound: SN-38	In-vitro inhibitory concentration for human tumor BEL-7402 cell-line was determined using MTT assay after 3 days of incubation In-vitro inhibitory concentration for human tumor BEL-7402 cell-line was determined using MTT assay after 3 days of incubation	[PMID: 15913996]
Bel-7402	IC₅₀	3.19 μM Compound: 7-Ethyl-10-hydroxycamptothecin (SN-38)	Inhibitory concentration against human Bel-7402 liver cancer cell line Inhibitory concentration against human Bel-7402 liver cancer cell line	[PMID: 15808456]
CAPAN-1	IC₅₀	8 nM Compound: SN38	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
CCD-841CoN	IC₅₀	4.98 μM Compound: 1d; SN38	Cytotoxicity against human CCD-841CoN cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human CCD-841CoN cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
COLO 205	IC₅₀	0.22 μM Compound: SN-38	Cytotoxicity against human COLO 205 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human COLO 205 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
COLO 205	IC₅₀	0.75 nM Compound: 2; SN38	Cytotoxicity against human COLO 205 cells incubated for 48 hrs by SRB assay Cytotoxicity against human COLO 205 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
Cancer cell lines	GI₅₀	0.066 μM Compound: SN-38	Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.066 μM Compound: SN-38	Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.066 μM Compound: SN-38	Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
DU-145	GI₅₀	4.3 nM Compound: 4; SN-38	Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay	[PMID: 30553626]
DU-145	IC₅₀	0.004 μM Compound: SN-38	Antiproliferative activity against human DU145 cells after 96 hrs Antiproliferative activity against human DU145 cells after 96 hrs	[PMID: 18276141]
DU-145	IC₅₀	0.013 μM Compound: SN-38	Antiproliferative activity against human DU145 prostate cell line Antiproliferative activity against human DU145 prostate cell line	[PMID: 10498216]
DU-145	IC₅₀	0.11 μM Compound: SN-38	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 23622981]
DU-145	IC₅₀	30 nM Compound: SN-38	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 23578545]
HCT-116	GI₅₀	0.02 μM Compound: SN-38	Growth inhibition of human HCT-116 cells by Cell-titer96 assay Growth inhibition of human HCT-116 cells by Cell-titer96 assay	[PMID: 33492141]
HCT-116	GI₅₀	23 nM Compound: 4; SN-38	Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 30553626]
HCT-116	IC₅₀	0.007 μM Compound: 7-Ethyl-10-hydroxycamptothecin (SN-38)	Inhibitory concentration against human HCT116 colon cancer cell line Inhibitory concentration against human HCT116 colon cancer cell line	[PMID: 15808456]
HCT-116	IC₅₀	0.01 μM Compound: SN-38	Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
HCT-116	IC₅₀	0.166 μM Compound: 5, SN-38	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 24529870]
HCT-116	IC₅₀	0.55 nM Compound: 14; SN-38	Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
HCT-116	IC₅₀	0.55 nM Compound: SN-38	Antiproliferative activity against human HCT116 cells after 3 days Antiproliferative activity against human HCT116 cells after 3 days	[PMID: 19254843]
HCT-116	IC₅₀	0.78 nM Compound: SN-38	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 30115492]
HCT-116	IC₅₀	3.3 nM Compound: SN-38	In-vitro inhibitory concentration for human tumor HCT116 cell-line was determined using MTT assay after 3 days of incubation In-vitro inhibitory concentration for human tumor HCT116 cell-line was determined using MTT assay after 3 days of incubation	[PMID: 15913996]
HCT-116	IC₅₀	31 nM Compound: 5, SN-38	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 3 days by SRB assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 24529870]
HCT-116	IC₅₀	4 nM Compound: SN38	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
HCT-116	IC₅₀	4.28 nM Compound: SN-38	Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay	[PMID: 25835359]
HCT-116	IC₅₀	54.93 nM Compound: 2; SN38	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by SRB assay Cytotoxicity against human HCT-116 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
HCT-116	IC₅₀	55.1 nM Compound: SN-38	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32679451]
HCT-116	IC₅₀	< 1 μM Compound: SN-38	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HCT-15	IC₅₀	0.008 μM Compound: SN-38	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
HEK-293T	IC₅₀	14.2 nM Compound: SN-38	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay	[PMID: 34963283]
HEK293	IC₅₀	360 μM Compound: SN-38	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method	[PMID: 21030469]
HEK293	IC₅₀	< 1 μM Compound: SN-38	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HL-60	IC₅₀	0.002 μM Compound: 1d; SN38	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
HL-60	IC₅₀	19 nM Compound: SN-38	In-vitro inhibitory concentration for human tumor HL60 cell-line was determined using SRB assay after 3 days of incubation In-vitro inhibitory concentration for human tumor HL60 cell-line was determined using SRB assay after 3 days of incubation	[PMID: 15913996]
HL-60	IC₅₀	2.4 μM Compound: SN-38	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HT-29	IC₅₀	0.0059 μM Compound: SN-38	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21470864]
HT-29	IC₅₀	0.012 μM Compound: SN-38	Antiproliferative activity against human HT29 cells after 96 hrs Antiproliferative activity against human HT29 cells after 96 hrs	[PMID: 18276141]
HT-29	IC₅₀	0.02 μM Compound: 1d; SN38	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
HT-29	IC₅₀	0.022 μM Compound: SN-38	Antiproliferative activity against human HT-29 colon cell line Antiproliferative activity against human HT-29 colon cell line	[PMID: 10498216]
HT-29	IC₅₀	0.054 μM Compound: SN-38	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
HT-29	IC₅₀	0.096 μM Compound: SN-38	Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
HT-29	IC₅₀	0.119 μM Compound: SN-38	Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
HT-29	IC₅₀	0.12 μM Compound: SN-38	Cytotoxicity against human HT-29 cells by SRB method Cytotoxicity against human HT-29 cells by SRB method	[PMID: 18986807]
HT-29	IC₅₀	0.17 μM Compound: 5, SN-38	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 19541483]
HT-29	IC₅₀	0.43 μM Compound: 2; SN38	Cytotoxicity against human HT-29 cells incubated for 48 hrs by SRB assay Cytotoxicity against human HT-29 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
HT-29	IC₅₀	0.67 μM Compound: SN-38	Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	106.67 nM Compound: 5, SN-38	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 3 days by SRB assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 24529870]
HT-29	IC₅₀	11.5 μM Compound: SN-38	Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	18.54 nM Compound: SN-38	Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay	[PMID: 25835359]
HT-29	IC₅₀	2.74 μM Compound: SN-38	Cytotoxicity against human HT-29 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
HT-29	IC₅₀	27.3 nM Compound: 3 (SN-38)	In vitro inhibitory concentration required against HT-29 human colon cancer cells In vitro inhibitory concentration required against HT-29 human colon cancer cells	[PMID: 12617927]
HT-29	IC₅₀	3.71 μM Compound: SN-38	Cytotoxicity against human HT-29 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
HT-29	IC₅₀	30 nM Compound: SN-38	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 23578545]
HeLa	IC₅₀	0.145 μM Compound: SN-38	Cytotoxicity against human Hela assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Hela assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
HeLa	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-positive human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-positive human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
HeLa	IC₅₀	13.1 μM Compound: SN-38	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
HeLa	IC₅₀	22 nM Compound: 14; SN-38	Cytotoxicity against human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
HeLa	IC₅₀	25.7 nM Compound: 1 (table 1)	Concentration required to inhibit growth of human cervical HeLa carcinoma cell line Concentration required to inhibit growth of human cervical HeLa carcinoma cell line	[PMID: 15454230]
HeLa	IC₅₀	349 nM Compound: SN38	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	38.8 nM Compound: 2 (table 1)	Concentration required to inhibit growth of human cervical HeLa carcinoma cell line Concentration required to inhibit growth of human cervical HeLa carcinoma cell line	[PMID: 15454230]
HeLa	IC₅₀	> 1 μM Compound: SN38	Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
Hep 3B2	GI₅₀	0.177 μM Compound: SN-38	Growth inhibition of human Hep3B cells by Cell-titer96 assay Growth inhibition of human Hep3B cells by Cell-titer96 assay	[PMID: 33492141]
HepG2	IC₅₀	0.48 μM Compound: SN38	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30600208]
HepG2	IC₅₀	480 nM Compound: 14; SN-38	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
Jurkat	IC₅₀	< 1 μM Compound: SN-38	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
KB 3-1	IC₅₀	0.004 μM Compound: SN-38	Cytotoxicity against human KB3-1 cells after 4 days by MTT method Cytotoxicity against human KB3-1 cells after 4 days by MTT method	[PMID: 19303306]
KB-V1	IC₅₀	0.046 μM Compound: SN-38	Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method	[PMID: 19303306]
L02	IC₅₀	18 nM Compound: SN38	Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
L1210	IC₅₀	0.04 μM Compound: SN-38	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 23578545]
L1210	IC₅₀	8.9 nM Compound: 14; SN-38	Cytotoxicity against mouse L1210 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
L1210	IC₅₀	8.9 nM Compound: 44	Inhibitory activity in mice bearing L1210 leukemia Inhibitory activity in mice bearing L1210 leukemia	[PMID: 1846923]
LNCaP	GI₅₀	0.0122 μM Compound: SN-38	Growth inhibition of human LNCaP cells by Cell-titer96 assay Growth inhibition of human LNCaP cells by Cell-titer96 assay	[PMID: 33492141]
LOX IMVI	GI₅₀	5.3 nM Compound: 4; SN-38	Antiproliferative activity against human LOXIMVI cells after 48 hrs by SRB assay Antiproliferative activity against human LOXIMVI cells after 48 hrs by SRB assay	[PMID: 30553626]
LoVo	IC₅₀	0.301 μM Compound: SN-38	Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
MCF7	GI₅₀	3 nM Compound: 4; SN-38	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 30553626]
MCF7	IC₅₀	0.1 nM Compound: 14; SN-38	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 38421819]
MCF7	IC₅₀	0.37 μM Compound: SN-38	Antiproliferative activity against human MCF-7 breast cell line Antiproliferative activity against human MCF-7 breast cell line	[PMID: 10498216]
MCF7	IC₅₀	0.515 μM Compound: SN-38	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
MCF7	IC₅₀	0.66 μM Compound: 1d; SN38	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
MCF7	IC₅₀	1.25 μM Compound: SN38	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30600208]
MCF7	IC₅₀	< 0.1 nM Compound: SN38	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 30169038]
MDA-MB-231	GI₅₀	0.512 μM Compound: SN-38	Growth inhibition of human MDA-MB-231 cells by Cell-titer96 assay Growth inhibition of human MDA-MB-231 cells by Cell-titer96 assay	[PMID: 33492141]
MDA-MB-231	IC₅₀	0.176 μM Compound: 5, SN-38	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 24529870]
MDA-MB-231	IC₅₀	1.97 μM Compound: SN-38	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
MDA-MB-435	IC₅₀	5 nM Compound: SN-38	Inhibition against MDA-MB-435 S human breast cancer cells in the absence of albumin Inhibition against MDA-MB-435 S human breast cancer cells in the absence of albumin	[PMID: 11052802]
MDA-MB-435	IC₅₀	50 nM Compound: SN-38	Inhibition against MDA-MB-435 S human breast cancer cells in the presence of 30 mg/mL HSA Inhibition against MDA-MB-435 S human breast cancer cells in the presence of 30 mg/mL HSA	[PMID: 11052802]
MDCK-II	GI₅₀	0.139 μM Compound: SN-38	Cytotoxicity against wild-type MDCK-II cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against wild-type MDCK-II cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33454462]
MIA PaCa-2	IC₅₀	13 nM Compound: SN38	Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
MKN-28	GI₅₀	110 nM Compound: 4; SN-38	Antiproliferative activity against human MKN28 cells after 48 hrs by SRB assay Antiproliferative activity against human MKN28 cells after 48 hrs by SRB assay	[PMID: 30553626]
MKN-45	IC₅₀	8 nM Compound: SN-38	In Vitro cytotoxicity against human stomach cancer cell line (MKN45) In Vitro cytotoxicity against human stomach cancer cell line (MKN45)	[PMID: 11334569]
MRC5	IC₅₀	15.3 μM Compound: SN-38	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
NCI-H128	IC₅₀	6 nM Compound: SN-38	In Vitro cytotoxicity against human lung cancer cell line (H128) In Vitro cytotoxicity against human lung cancer cell line (H128)	[PMID: 11334569]
NCI-H1975	IC₅₀	0.81 μM Compound: SN-38	Cytotoxicity against human NCI-H1975 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
NCI-H226	GI₅₀	0.277 μM Compound: SN-38	Growth inhibition of human NCI-H226 cells by Cell-titer96 assay Growth inhibition of human NCI-H226 cells by Cell-titer96 assay	[PMID: 33492141]
NCI-H460	IC₅₀	0.047 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
NCI-H460	IC₅₀	0.05 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
NCI-H460	IC₅₀	0.05 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay	[PMID: 28740613]
NCI-H460	IC₅₀	0.06 μM Compound: SN-38	Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay	[PMID: 28350997]
NCI-H460	IC₅₀	0.08 μM Compound: SN-38	Inhibition of human H460 cell growth Inhibition of human H460 cell growth	[PMID: 16913706]
NCI-H460	IC₅₀	0.13 μM Compound: SN-38	Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium	[PMID: 19530720]
NCI-H460	IC₅₀	0.21 μM Compound: SN-38	In vitro inhibitory concentration against human lung large cell carcinoma cell line, H460 (after 1 hour exposure) In vitro inhibitory concentration against human lung large cell carcinoma cell line, H460 (after 1 hour exposure)	[PMID: 15501036]
NCI-H460	IC₅₀	0.22 μM Compound: SN-38	Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
NCI-H460	IC₅₀	0.22 μM Compound: SN-38	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 18434153]
NCI-H460	IC₅₀	3.3 nM Compound: SN-38	Antiproliferative activity against human NCI-H460 cells after 3 days Antiproliferative activity against human NCI-H460 cells after 3 days	[PMID: 19254843]
NCI-H522	GI₅₀	3.7 nM Compound: 4; SN-38	Antiproliferative activity against human NCI-H522 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-H522 cells after 48 hrs by SRB assay	[PMID: 30553626]
P388	IC₅₀	1.44 ng/mL Compound: 5 (SN-38)	In vitro antitumor activity against P388 (murine leukemia) cells. In vitro antitumor activity against P388 (murine leukemia) cells.	[PMID: 9632364]
P388	IC₅₀	6.93 ng/mL Compound: 5	Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay; 1.95-6.93 ng/mL Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay; 1.95-6.93 ng/mL	[PMID: 7932525]
PC-3	IC₅₀	0.0026 μM Compound: 3, SN38	Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
PC-3	IC₅₀	35.3 nM Compound: 2 (table 1)	Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line	[PMID: 15454230]
PC-3	IC₅₀	35.6 nM Compound: 1 (table 1)	Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line	[PMID: 15454230]
PC-6	IC₅₀	0.43 nM Compound: SN-38	Antiproliferative activity against human PC6 cells carrying pRC after 6 days Antiproliferative activity against human PC6 cells carrying pRC after 6 days	[PMID: 19254843]
PC-6	IC₅₀	5.1 nM Compound: SN-38	Antiproliferative activity against human PC6 expressing BCRP cells after 6 days Antiproliferative activity against human PC6 expressing BCRP cells after 6 days	[PMID: 19254843]
QG-56	IC₅₀	0.9 ng/mL Compound: 5 (SN-38)	In vitro antitumor activity against QG-56 (human lung cancer) cells. In vitro antitumor activity against QG-56 (human lung cancer) cells.	[PMID: 9632364]
QG-56	IC₅₀	2.8 nM Compound: SN-38	Antiproliferative activity against human QG56 cells after 3 days Antiproliferative activity against human QG56 cells after 3 days	[PMID: 19254843]
QG-56	IC₅₀	3.17 ng/mL Compound: 5	Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay	[PMID: 7932525]
RPMI-7951	IC₅₀	0.26 μM Compound: SN 38	Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
Raji	IC₅₀	0.005 μM Compound: SN-38	Cytotoxicity against human Raji assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Raji assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
SAOS-2	IC₅₀	176 nM Compound: SN-38	TP_TRANSPORTER: drug resistance(Imatinib mesylate) in BCRP-expressing SaoS2 cells TP_TRANSPORTER: drug resistance(Imatinib mesylate) in BCRP-expressing SaoS2 cells	[PMID: 15059881]
SJRH30	GI₅₀	0.0093 μM Compound: SN-38	Growth inhibition of human SJRH30 cells by Cell-titer96 assay Growth inhibition of human SJRH30 cells by Cell-titer96 assay	[PMID: 33492141]
SK-BR-3	IC₅₀	4 nM Compound: SN-38	In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3) In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3)	[PMID: 11334569]
SK-HEP1	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-positive human SKHEP1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-positive human SKHEP1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
SK-MEL-24	IC₅₀	0.48 μM Compound: SN 38	Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
SK-OV-3	GI₅₀	23 nM Compound: 4; SN-38	Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 30553626]
SK-OV-3	IC₅₀	0.72 μM Compound: SN-38	Antiproliferative activity against human SKOV-3 ovarian cell line Antiproliferative activity against human SKOV-3 ovarian cell line	[PMID: 10498216]
SK-OV-3	IC₅₀	11 nM Compound: SN-38	In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3) In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3)	[PMID: 11334569]
SiHa	IC₅₀	0.3 μM Compound: SN38	Cytotoxicity against FR-positive human SiHa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against FR-positive human SiHa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32832017]
TE-8	IC₅₀	< 1 μM Compound: SN-38	Cytotoxicity against human TE8 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay Cytotoxicity against human TE8 cells assessed as reduction in cell viability incubated for 48 hrs by WST8 dye based assay	[PMID: 30935798]
U-251	GI₅₀	2.8 nM Compound: 4; SN-38	Antiproliferative activity against human U251 cells after 48 hrs by SRB assay Antiproliferative activity against human U251 cells after 48 hrs by SRB assay	[PMID: 30553626]
U-251	IC₅₀	0.021 μM Compound: SN-38	Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
U-87MG ATCC	IC₅₀	0.03 μM Compound: SN-38	Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 27060760]
WiDr	IC₅₀	14 nM Compound: SN-38	In Vitro cytotoxicity against human colon cancer cell line (WiDr) In Vitro cytotoxicity against human colon cancer cell line (WiDr)	[PMID: 11334569]
carcinoma cell line	IC₅₀	0.08 μM Compound: SN-38	Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460) Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460)	[PMID: 11563925]

体外研究
(In Vitro)

LoVo、HCT116 和 HT29 细胞系的 IC₅₀ 值分别为 20 nM、50 nM、130 nM。在所有三种 SN-38 耐药细胞系中，在高浓度 SN-38 存在下，Top1 活性得以维持^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

SN-38 是抗癌前药伊立替康的活性和毒性代谢物。给药 30 分钟后，Slco1a/1b(-/-) 小鼠的伊立替康血浆浓度比野生型小鼠高 1.9 倍（分别为 1.89 μM 和 1.01 μM），而 <Slco1a/1b(-/-)小鼠的 SN-38 血浆浓度比野生型小鼠高 8 倍（分别为 0.4 μg/mL 和 0.05 μg/mL）。与野生型小鼠相比，Oatp1a/1b 基因敲除小鼠的伊立替康总血浆暴露量 [AUC_(5-240)] 高 1.7 倍（209.8±6.7 vs. 120.9±4.4 μM/min；P<0.01），SN-38 小鼠的伊立替康总血浆暴露量高 2.9 倍 (50±2.9 vs. 12±2 μM/min；P<0.001)^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

392.40

Formula

C₂₂H₂₀N₂O₅

CAS 号

86639-52-3

性状

固体

颜色

Off-white to yellow

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : 25 mg/mL (63.71 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5484 mL	12.7421 mL	25.4842 mL
5 mM	0.5097 mL	2.5484 mL	5.0968 mL
10 mM	0.2548 mL	1.2742 mL	2.5484 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: 2.5 mg/mL (6.37 mM); 悬浊液; 超声助溶

此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案二

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (5.30 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案三

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.30 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.94%

选择批次：

Data Sheet (644 KB) SDS (479 KB)

COA (291 KB) HNMR (293 KB) RP-HPLC (246 KB) LCMS (95 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19(6):1493-8. [Content Brief]

[2]. Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56. [Content Brief]

[3]. Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187-4191. [Content Brief]

[4]. Aaron T Jacobs, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct:204:115209. [Content Brief]

Cell Assay ^[2]	In vitro SN-38 sensitivity is determined using the MTT assay. Cells are seeded in 96-well plates, and a range of SN-38 concentrations is added the following day. Following 48 h of drug exposure, the medium is discarded and the plates are incubated with medium containing MTT (0.5 mg/mL) for 3 h. Acidified (0.02 M HCl) sodium dodecyl sulphate (20 %) is added to dissolve the formed formazan. Optical density at 570 nm (and 670 nm for background) is measured, and the cell viability is calculated in percent compared to untreated cells. Experiments are repeated three times and the mean IC₅₀ value ± standard deviation is determined. Relative resistance for each resistant cell line is calculated by dividing the mean IC₅₀ value of the resistant cell line by the mean IC₅₀ value of the corresponding parental cell line^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] Female wild-type, Slco1a/1b(−/−)(Oatp1a/1b knockout), Slco1a/1b(−/−);1B1(tg), and Slco1a/1b(−/−);1B3(tg) (liver-specific OATP1B1 and OATP1B3 humanized transgenic) mice of comparable genetic background (>99% FVB) between 8 and 14 weeks of age are used. Irinotecan (20 mg/mL in water-based solution containing NaOH, lactic acid, and sorbitol) is diluted with saline (to 2 mg/mL) for administration of 10 mg/kg; 5 μL/g bodyweight are administered intravenously to mice. SN-38 is dissolved in DMSO (1 mg/mL) and 1 μL/g body weight is administered intravenously to mice to achieve a dosage of 1 mg/kg. The experiments are terminated by isoflurane anaesthesia, heparin-blood sampling by cardiac puncture followed by cervical dislocation and tissue collection. Blood samples are centrifuged at 5,200 × g for 5 minutes at 4°C and plasma is collected and stored at −30°C until analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19(6):1493-8. [Content Brief] [2]. Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56. [Content Brief] [3]. Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187-4191. [Content Brief] [4]. Aaron T Jacobs, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct:204:115209. [Content Brief]

SN-38 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5484 mL	12.7421 mL	25.4842 mL	63.7105 mL
	5 mM	0.5097 mL	2.5484 mL	5.0968 mL	12.7421 mL
	10 mM	0.2548 mL	1.2742 mL	2.5484 mL	6.3711 mL
	15 mM	0.1699 mL	0.8495 mL	1.6989 mL	4.2474 mL
	20 mM	0.1274 mL	0.6371 mL	1.2742 mL	3.1855 mL
	25 mM	0.1019 mL	0.5097 mL	1.0194 mL	2.5484 mL
	30 mM	0.0849 mL	0.4247 mL	0.8495 mL	2.1237 mL
	40 mM	0.0637 mL	0.3186 mL	0.6371 mL	1.5928 mL
	50 mM	0.0510 mL	0.2548 mL	0.5097 mL	1.2742 mL
	60 mM	0.0425 mL	0.2124 mL	0.4247 mL	1.0618 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SN-3886639-52-37-Ethyl-10-hydroxycamptothecinSN38SN 38Drug MetaboliteTopoisomeraseADC PayloadAutophagyADC CytotoxinInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

SN-38 (Synonyms: 7-Ethyl-10-hydroxycamptothecin)

Customer Review

Other Forms of SN-38:

MCE 顾客使用本产品发表的 69 篇科研文献

SN-38 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看 ADC Payload 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

SN-38 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

SN-38 (Synonyms: 7-Ethyl-10-hydroxycamptothecin)

Customer Review

Other Forms of SN-38:

SN-38 相关抗体

MCE 顾客使用本产品发表的 69 篇科研文献

SN-38 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看 ADC Payload 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

SN-38 相关抗体:

摩尔计算器

稀释计算器

SN-38 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z